Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: Use of dasatinib and reduced-conditioning stem-cell transplantation [10]

Leukemia

Volumn 21, Issue 11, 2007, Pages 2376-2377

  Corm, S ^a,b   Renneville, A ^a,b   Rad Quesnel, E ^c   Grardel, N ^a,b   Preudhomme, C ^a,b   Quesnel, B ^a,b  

^a UNIV LILLE   (France)

^b Institut de Recherche sur le Cancer de Lille   (France)

^c CENTRE HOSPITALIER DE ROUBAIX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; CYTARABINE; DASATINIB; FLUDARABINE; HYBRID PROTEIN; IDARUBICIN; IMATINIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW BIOPSY; CARDIOMEGALY; CASE REPORT; CONTINUOUS INFUSION; CONVULSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GENERALIZED EDEMA; GRAFT VERSUS HOST REACTION; HOSPITAL ADMISSION; HUMAN; LETTER; LEUKEMIA RELAPSE; MONOTHERAPY; PATIENT REFERRAL; PATIENT TRANSPORT; PLEURA DISEASE; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 35548936086     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404792     Document Type: Letter

References (9)

1. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U et al. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 1996; 88: 2236-2240.
2. Dupont M, Jourdan E, Chiesa J. Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML. Leukemia 2000; 14: 2011-2012.
3. Schultheis B, Wang L, Clark RE, Melo JV. BCR-ABL with an e6a2-fusion in a CML patient diagnosed in blast crisis. Leukemia 2003; 17: 2054-2055.
4. Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N. e6a2 BCR-ABL transcript in chronic myeloid leukemia: Is it associated with aggressive disease? Haematologica 2004; 89: 611-613.
5. Hayette S, Tigaud I, Thomas X, French M, Perrin MC, Nicolini F et al. Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: A case report. Leukemia 2004; 18: 1735-1736.
6. Popovici C, Cailleres S, David M, Lafage-Pochital off M, Sainty D, Mozziconacci MJ. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib. Leuk Lymphoma 2005; 46: 1375-1377.
7. Roti G, La Starza R, Gorello P, Gottardi E, Crescenzi B, Martelli MF et al. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. Haematologica 2005; 90 1139-1141.
8. Gregoire MJ, Latger-Cannard V, Staal A, Bologna S, Leotard B, Rault JP et al. Identification of an acute basophilic leukaemia carrying a rare e6a2 BCR-ABL transcript. Acta Haematol 2006; 116: 216-218.
9. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207-3213.